These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36223548)

  • 1. IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression.
    Lapadula D; Lam B; Terai M; Sugase T; Tanaka R; Farias E; Kadamb R; Lopez-Anton M; Heine CC; Modasia B; Aguirre-Ghiso JA; Aplin AE; Sato T; Benovic JL
    Mol Cancer Ther; 2023 Jan; 22(1):63-74. PubMed ID: 36223548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
    Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
    J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and evaluation of quinazoline derivatives as Gαq/11 proteins inhibitors against uveal melanoma.
    Fan G; Liu L; Ye J; Xiao W; Xiong XF
    Bioorg Chem; 2024 Feb; 143():107005. PubMed ID: 38043397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Oncogenic Gα
    Lapadula D; Farias E; Randolph CE; Purwin TJ; McGrath D; Charpentier TH; Zhang L; Wu S; Terai M; Sato T; Tall GG; Zhou N; Wedegaertner PB; Aplin AE; Aguirre-Ghiso J; Benovic JL
    Mol Cancer Res; 2019 Apr; 17(4):963-973. PubMed ID: 30567972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct targeting of Gα
    Annala S; Feng X; Shridhar N; Eryilmaz F; Patt J; Yang J; Pfeil EM; Cervantes-Villagrana RD; Inoue A; Häberlein F; Slodczyk T; Reher R; Kehraus S; Monteleone S; Schrage R; Heycke N; Rick U; Engel S; Pfeifer A; Kolb P; König G; Bünemann M; Tüting T; Vázquez-Prado J; Gutkind JS; Gaffal E; Kostenis E
    Sci Signal; 2019 Mar; 12(573):. PubMed ID: 30890659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Inhibition of Gα
    Hitchman TD; Bayshtok G; Ceraudo E; Moore AR; Lee C; Jia R; Wang N; Pachai MR; Shoushtari AN; Francis JH; Guan Y; Chen J; Chang MT; Taylor BS; Sakmar TP; Huber T; Chi P; Chen Y
    Clin Cancer Res; 2021 Mar; 27(5):1476-1490. PubMed ID: 33229459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulator of G protein signaling 2 inhibits Gα
    Zhang Q; Haak AJ; Sjögren B
    J Biol Chem; 2022 Jun; 298(6):101955. PubMed ID: 35452684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
    Glinkina KA; Teunisse AFAS; Gelmi MC; de Vries J; Jager MJ; Jochemsen AG
    Melanoma Res; 2023 Oct; 33(5):345-356. PubMed ID: 37467061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional characterization of uveal melanoma oncogenes.
    Ma J; Weng L; Bastian BC; Chen X
    Oncogene; 2021 Jan; 40(4):806-820. PubMed ID: 33262460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic Gq/11 signaling acutely drives and chronically sustains metabolic reprogramming in uveal melanoma.
    Onken MD; Noda SE; Kaltenbronn KM; Frankfater C; Makepeace CM; Fettig N; Piggott KD; Custer PL; Ippolito JE; Blumer KJ
    J Biol Chem; 2022 Jan; 298(1):101495. PubMed ID: 34919964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.
    Yu FX; Luo J; Mo JS; Liu G; Kim YC; Meng Z; Zhao L; Peyman G; Ouyang H; Jiang W; Zhao J; Chen X; Zhang L; Wang CY; Bastian BC; Zhang K; Guan KL
    Cancer Cell; 2014 Jun; 25(6):822-30. PubMed ID: 24882516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research in practice: Therapeutic targeting of oncogenic GNAQ mutations in uveal melanoma.
    Gaffal E
    J Dtsch Dermatol Ges; 2020 Nov; 18(11):1245-1248. PubMed ID: 32954611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.
    Baqai U; Kurimchak AM; Trachtenberg IV; Purwin TJ; Haj JI; Han A; Luo K; Pachon NF; Jeon A; Chua V; Davies MA; Gutkind JS; Benovic JL; Duncan JS; Aplin AE
    J Biol Chem; 2023 Dec; 299(12):105418. PubMed ID: 37923138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.
    Arang N; Lubrano S; Ceribelli M; Rigiracciolo DC; Saddawi-Konefka R; Faraji F; Ramirez SI; Kim D; Tosto FA; Stevenson E; Zhou Y; Wang Z; Bogomolovas J; Molinolo AA; Swaney DL; Krogan NJ; Yang J; Coma S; Pachter JA; Aplin AE; Alessi DR; Thomas CJ; Gutkind JS
    Cell Rep Med; 2023 Nov; 4(11):101244. PubMed ID: 37858338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
    Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palmitoylation of GNAQ/11 is critical for tumor cell proliferation and survival in GNAQ/11-mutant uveal melanoma.
    Zhang Y; Zhang B; Li Y; Dai Y; Li J; Li D; Xia Z; Zhang J; Liu P; Chen M; Jiao B; Ren R
    Front Med; 2022 Oct; 16(5):784-798. PubMed ID: 35997986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for
    Paradis JS; Acosta M; Saddawi-Konefka R; Kishore A; Gomes F; Arang N; Tiago M; Coma S; Lubrano S; Wu X; Ford K; Day CP; Merlino G; Mali P; Pachter JA; Sato T; Aplin AE; Gutkind JS
    Clin Cancer Res; 2021 Jun; 27(11):3190-3200. PubMed ID: 33568347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
    Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
    Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression.
    Li H; Li Q; Dang K; Ma S; Cotton JL; Yang S; Zhu LJ; Deng AC; Ip YT; Johnson RL; Wu X; Punzo C; Mao J
    Cell Rep; 2019 Dec; 29(10):3200-3211.e4. PubMed ID: 31801083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined PKC and MEK inhibition for treating metastatic uveal melanoma.
    Sagoo MS; Harbour JW; Stebbing J; Bowcock AM
    Oncogene; 2014 Sep; 33(39):4722-3. PubMed ID: 24413085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.